FENTIAZAC

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H12ClNO2S
Molecular Weight	329.801
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=JIEKMACRVQTPRC-UHFFFAOYSA-N

InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)

HIDE SMILES / InChI

Description

Fentiazac is a non-steroidal anti-inflammatory agent developed for the treatment of pain disorders. The drug was marketed under the name Norvedan, however, its current marketing status is unknown and supposed to be "discontinued".

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619	Primary		Approved 8,583	NORVEDAN

C_max

Value	Dose	Analyte	Population
2670 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
3450 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
4080 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
1990 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
1500 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
1240 ng/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
5.4 mg/L	200 mg single, oral	FENTIAZAC plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
4490 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
5200 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
5670 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
5770 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
5510 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens
3400 ng × h/mL	200 mg 2 times / day steady-state, oral	FENTIAZAC plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
7 h	200 mg single, oral		FENTIAZAC plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
200 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT	Disc. AE: Rash...
400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT	Disc. AE: Itching, Skin eruption...
400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT	Disc. AE: Epigastric pain, Gastric ulcer...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Rash	grade 3, 5.3% Disc. AE	200 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT
Epigastric pain	grade 2, 5% Disc. AE	400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT
Headache	grade 2, 5% Disc. AE	400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT
Itching	grade 2, 5% Disc. AE	400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT
Skin eruption	grade 2, 5% Disc. AE	400 mg 1 times / day multiple, oral Studied dose	unhealthy, ADULT

Showing 1 to 5 of 8 entries

Previous1 2Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

6,44 mg/kg as a daily dose.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Show entries

Name

Type

Language

FENTIAZAC

Official Name

English

NSC-282191

Preferred Name

English

4-(P-CHLOROPHENYL)-2-PHENYL-5-THIAZOLEACETIC ACID

Common Name

English

FENTIAZAC [USAN]

Common Name

English

Fentiazac [WHO-DD]

Common Name

English

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Antiinflammatory preparations, non-steroids for topical use

WHO-ATC

M02AA14

Acetic acid derivatives and related substances

WHO-ATC

M01AB10

Acetic acid derivatives and related substances

WHO-VATC

QM01AB10

Nonsteroidal Antiinflammatory Drug

NCI_THESAURUS

C1323

Antiinflammatory preparations, non-steroids for topical use

WHO-VATC

QM02AA14

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

ECHA (EC/EINECS)

241-958-1

PRIMARY

MESH

C006124

PRIMARY

NSC

282191

PRIMARY

SMS_ID

100000081508

PRIMARY

DRUG CENTRAL

1165

PRIMARY

Showing 1 to 5 of 17 entries

Previous1 2 3 4Next

ACTIVE MOIETY


					0YHF6E6NLS

FENTIAZAC

SALT/SOLVATE (PARENT)


					87K2GQ2Q21

FENTIAZAC CALCIUM

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="http://imr.sagepub.com/content/11/5/298.full.pdf">http://imr.sagepub.com/content/11/5/298.full.pdf</a></span></span></div></div>

Approval Year

Conditions

Cmax

AUC

T1/2

Doses

AEs

PubMed

Patents

Sample Use Guides

Description

C_max

T_1/2